Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue Estimates

分组1 - Tarsus Pharmaceuticals reported a quarterly loss of $0.3 per share, which was better than the Zacks Consensus Estimate of a loss of $0.35, and an improvement from a loss of $0.61 per share a year ago, resulting in an earnings surprise of +14.29% [1] - The company achieved revenues of $118.7 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 2.80%, and showing significant growth from $48.12 million in the same quarter last year [2] - Tarsus Pharmaceuticals has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has increased approximately 26% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.10 on revenues of $127.92 million, and for the current fiscal year, it is -$1.62 on revenues of $428.6 million [7] - The Medical - Biomedical and Genetics industry, to which Tarsus Pharmaceuticals belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]